A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. - Gan HK; Parakh S; Lee FT; Tebbutt NC; Ameratunga M; Lee ST; O'Keefe GJ; Gong SJ; Vanrenen C; Caine J; Giovannetti M; Murone C; et al. (Investigational new drugs, 2022)